Should we Cut Back on IVF?
By Lara Salahi,
The Boston Globe
| 01. 29. 2014
In vitro fertilization (IVF) has given about 5 percent of couples who suffer from infertility a shot at parenthood. But are we overusing the technology without clearly understanding its risks? Yes, say a group of European researchers who came to the conclusion by reviewing studies on women who underwent the procedure and the health of children born using the technology.
IVF was originally approved for use in women with fallopian tube disorders and men who suffered with infertility. Today IVF is used with couples with other types of
infertility-related disorders -- including unexplained infertility. In their analysis
published Tuesday in the British Medical Journal, the European researchers say we may be overusing IVF to treat an expanded list of conditions without clear evidence that it will be effective. Even if it does work, the procedure is performed without knowing what the risks may be for the women or IVF-born children later on.
Although it’s has been around since the late 1970s, there’s a lot we still don’t know about IVF. More than 60,000 children with born through IVF...
Related Articles
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
Alice Wong, founder of the Disability Visibility Project, MacArthur Genius, liberationist, storyteller, writer, and friend of CGS, died on November 14. Alice shone a bright light on pervasive ableism in our society. She articulated how people with disabilities are limited not by an inability to do things but by systemic segregation and discrimination, the de-prioritization of accessibility, and the devaluation of their lives.
We at CGS learned so much from Alice about disability justice, which goes beyond rights...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...